Abstract: A method of treating central nervous system (CNS) diseases in a subject is provided. The method comprises administering to the subject a therapeutically effective amount of Antcin H and/or its derivatives. The novel use of Antcin H and/or its derivatives are also provided.

Abstract: Disclosed herein are a method of treating, reducing the risk of, preventing, or alleviating angiotensin converting enzyme 2 (ACE-2) associated state in a subject, comprising administering to the subject a therapeutically effective amount of Antrodia cinnamomea extract (Ant-Ex) or fraction 3 thereof (AE-F03). Also provided herein are uses of Ant-Ex or AE-F03 in reducing ACE-2 expression and manufacturing a drug or a food supplement for treating, reducing the risk of, preventing, or alleviating ACE-2 associated state.

Abstract: The present invention discloses use of a polyenylpyrrole derivative in preparation of an anti-oral cancer drugs. The polyenylpyrrole derivative synthesized by polyvinylpyrrole, auxarconjugatin A and 12E-isorumbrin inhibits the cell proliferation, migration, tumor sphere formation abilities and xenograft tumorigenicity of oral cancer cells.

Abstract: The present invention discloses a new use of ginsenoside M1 for treating or preventing silicosis.

Abstract: The present invention discloses a new use of ginsenoside M1 for treating or preventing gout.

Abstract: The present invention discloses a new use of ginsenoside M1 for treating or preventing gout.

Abstract: The present invention discloses a new use of ginsenoside M1 for treating or preventing silicosis.

Abstract: The present invention provides a method of inhibiting renal fibrosis in a subject in need thereof.

Abstract: The present invention relates to use of osthole for manufacturing a composition for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that osthole is effective in treating focal segmental glomerulosclerosis (FSGS), which can alleviate various symptoms and signs of FSGS, including proteinuria, renal fibrosis, glomerular epithelial hyperplasia lesion (EPHL), and macrophage/lymphocyte infiltration in the kidney, etc.

Abstract: The present invention relates to a new use of a cinnamaldehyde derivative of formula (I) for treating glomerulonephritis (GN). Particularly, the present invention discloses that the cinnamaldehyde derivative of formula (I) is effective in treating glomerulonephritis (GN), which can alleviate various symptoms and signs of GN, including reducing proteinuria, serum blood urea nitrogen (BUN), glomerular cell proliferation, and renal macrophage/lymphocyte infiltration, etc.

Abstract: The present invention relates to use of osthole for manufacturing a composition for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that osthole is effective in treating focal segmental glomerulosclerosis (FSGS), which can alleviate various symptoms and signs of FSGS, including proteinuria, renal fibrosis, glomerular epithelial hyperplasia lesion (EPHL), and macrophage/lymphocyte infiltration in the kidney, etc.

Abstract: The present invention relates to a new use of a cinnamaldehyde derivative of formula (I) for treating glomerulonephritis (GN). Particularly, the present invention discloses that the cinnamaldehyde derivative of formula (I) is effective in treating glomerulonephritis (GN), which can alleviate various symptoms and signs of GN, including reducing proteinuria, serum blood urea nitrogen (BUN), glomerular cell proliferation, and renal macrophage/lymphocyte infiltration, etc.

Abstract: The present invention relates to a new use of citral for manufacturing a medicament for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that citral is effective in alleviating symptoms of FSGS, including reducing glomerular epithelial hyperplasia lesions (EPHLs), peri-glomerular inflammation or glomerular hyalinosis or sclerosis, and also reducing proteinuria or hematuria or lowering serum urea nitrogen level or serum creatinine level in the subject.

Abstract: The present invention relates to a method for treating inflammatory disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of 2-methoxy-4-methylphenol or a pharmaceutically acceptable salt or a physiologically functional derivative thereof, wherein the compound is in a therapeutically effective amount to inhibit NO or IL-6 expression, caspase-1 activation or IL-1? secretion, and NLRP3 and IL-1? precursor expression in inflammatory cells of the subject.

Abstract: The present invention relates to a new use of citral for manufacturing a medicament for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that citral is effective in alleviating symptoms of FSGS, including reducing glomerular epithelial hyperplasia lesions (EPHLs), peri-glomerular inflammation or glomerular hyalinosis or sclerosis, and also reducing proteinuria or hematuria or lowering serum urea nitrogen level or serum creatinine level in the subject.

Abstract: The present invention relates to a method for treating inflammation comprising administering a subject in need thereof with a therapeutically effective amount of a composition comprising bamboo vinegar or the phenolic fraction thereof. The method for preparing the phenolic fraction is also provided.

Abstract: The preset invention relates to a method for treating inflammation comprising administering a subject in need thereof with a therapeutically effective amount of a composition comprising bamboo vinegar or the phenolic fraction thereof. The method for preparing the phenolic fraction is also provided.

Abstract: The present disclosure provides methods for increasing the lipopolysaccharide-induced secretion of IL-1 by macrophages, for increasing serum levels of IL-1 in a mammal, for increasing the serum level of IL-1 receptor antagonist (IL-1Ra) in a mammal, for increasing the secretion of IL-1 by a monocyte, for increasing the secretion of IL-1Ra by a monocyte, for increasing the secretion of IL-1Ra by a macrophage, for increasing expression of TLR4 on the surface of a macrophage, for increasing expression of CD14 on the surface of macrophage, for increasing the uptake and clearance of lipopolysaccharide (LPS) by a LPS-stimulated macrophage, and for increasing lipopolysaccharide (LPS)-stimulated activation of at least one of ERK, JNK, and p38 in a macrophage. The methods of the disclosure involve the administration to mammals and immune cells of a fucose-containing glycoprotein fraction from Ganoderma lucidum.

Abstract: The present disclosure provides methods for increasing the lipopolysaccharide-induced secretion of IL-1 by macrophages, for increasing serum levels of IL-1 in a mammal, for increasing the serum level of IL-1 receptor antagonist (IL-1Ra) in a mammal, for increasing the secretion of IL-1 by a monocyte, for increasing the secretion of IL-1Ra by a monocyte, for increasing the secretion of IL-1Ra by a macrophage, for increasing expression of TLR4 on the surface of a macrophage, for increasing expression of CD14 on the surface of macrophage, for increasing the uptake and clearance of lipopolysaccharide (LPS) by a LPS-stimulated macrophage, and for increasing lipopolysaccharide (LPS)-stimulated activation of at least one of ERK, JNK, and p38 in a macrophage. The methods of the disclosure involve the administration to mammals and immune cells of a fucose-containing glycoprotein fraction from Ganoderma lucidum.